Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, has provided an update regarding its Definitive Agreement with Predictive Oncology Predictive Oncology, Inc. (NASDAQ: POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. On April 3, 2025, Renovaro received an email from POI terminating the merger transaction. Renovaro’s position is that POI must comply with the binding obligations thereunder and enter into an exclusive License Agreement as required in each of the Binding Agreements.
Read the full article: Renovaro Provides Update to Definitive Agreement with Predictive Oncology //
Source: https://www.globenewswire.com/news-release/2025/04/04/3056001/0/en/Renovaro-Provides-Update-to-Definitive-Agreement-with-Predictive-Oncology.html